tetano
Editor, Senior Moderator
J Med Virol
. 2024 Jan;96(1):e29279.
doi: 10.1002/jmv.29279. Cost-effectiveness analysis of cell-based versus egg-based quadrivalent influenza vaccines in the pediatric population in Taiwan
Chia-Yu Chi[SUP] 1 [/SUP], Ming-Fang Cheng[SUP] 2 [/SUP], Karam Ko[SUP] 3 [/SUP], Joaquin F Mould[SUP] 4 [/SUP], Chih-Jung Chen[SUP] 5 [/SUP], Yhu-Chering Huang[SUP] 5 [/SUP], Ping-Ing Lee[SUP] 6 [/SUP]
Affiliations
Cell-based influenza vaccines avoid egg-adaptive mutations, potentially improving vaccine effectiveness. We assessed the one-season cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) against that of egg-derived quadrivalent influenza vaccines (QIVe) in children (6 months to 17 years of age) from payer and societal perspectives in Taiwan using an age-stratified static model. Base case and high egg adaptation scenarios were assessed. Deterministic and probabilistic sensitivity analyses were performed. The incremental cost-effectiveness ratio (ICER) threshold in Taiwan was assumed to be USD 99 177/quality-adjusted life year (QALY). Compared to QIVe, QIVc would prevent 15 665 influenza cases, 2244 complicated cases, and 259 hospitalizations per year. The base case ICER was USD 68 298/QALY and USD 40 085/QALY from the payer and societal perspective, respectively. In the high egg adaptation scenario, the ICER was USD 45 782/QALY from the payer's perspective and USD 17 489/QALY from the societal perspective. Deterministic sensitivity analyses indicated that infection incidence rate, vaccination coverage, and prevalence of the A/H3N2 strain were the main drivers of ICER. In conclusion, switching the immunization strategy from QIVe to QIVc is predicted to reduce the influenza-associated disease burden and be cost-effective for the pediatric population in Taiwan. The potential benefits of QIVc would be even higher during influenza seasons with high levels of egg adaptation.
Keywords: Taiwan; cell-based quadrivalent influenza vaccine; cost-effectiveness; influenza; pediatric population.
. 2024 Jan;96(1):e29279.
doi: 10.1002/jmv.29279. Cost-effectiveness analysis of cell-based versus egg-based quadrivalent influenza vaccines in the pediatric population in Taiwan
Chia-Yu Chi[SUP] 1 [/SUP], Ming-Fang Cheng[SUP] 2 [/SUP], Karam Ko[SUP] 3 [/SUP], Joaquin F Mould[SUP] 4 [/SUP], Chih-Jung Chen[SUP] 5 [/SUP], Yhu-Chering Huang[SUP] 5 [/SUP], Ping-Ing Lee[SUP] 6 [/SUP]
Affiliations
- PMID: 38196182
- DOI: 10.1002/jmv.29279
Cell-based influenza vaccines avoid egg-adaptive mutations, potentially improving vaccine effectiveness. We assessed the one-season cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) against that of egg-derived quadrivalent influenza vaccines (QIVe) in children (6 months to 17 years of age) from payer and societal perspectives in Taiwan using an age-stratified static model. Base case and high egg adaptation scenarios were assessed. Deterministic and probabilistic sensitivity analyses were performed. The incremental cost-effectiveness ratio (ICER) threshold in Taiwan was assumed to be USD 99 177/quality-adjusted life year (QALY). Compared to QIVe, QIVc would prevent 15 665 influenza cases, 2244 complicated cases, and 259 hospitalizations per year. The base case ICER was USD 68 298/QALY and USD 40 085/QALY from the payer and societal perspective, respectively. In the high egg adaptation scenario, the ICER was USD 45 782/QALY from the payer's perspective and USD 17 489/QALY from the societal perspective. Deterministic sensitivity analyses indicated that infection incidence rate, vaccination coverage, and prevalence of the A/H3N2 strain were the main drivers of ICER. In conclusion, switching the immunization strategy from QIVe to QIVc is predicted to reduce the influenza-associated disease burden and be cost-effective for the pediatric population in Taiwan. The potential benefits of QIVc would be even higher during influenza seasons with high levels of egg adaptation.
Keywords: Taiwan; cell-based quadrivalent influenza vaccine; cost-effectiveness; influenza; pediatric population.